SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Cerexa expands portfolio of novel anti-infective therapies through in-licensing agreement with Meiji Seika Kaisha
News | 11. 01. 2006
Cerexa
Cerexa Inc. today announced it has expanded its portfolio of novel anti-infective therapies through an in-licensing agreement with Meiji Seika Kaisha Ltd.
